rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Pliant Therapeutics, Inc.

PLRX · Nasdaq

Health CareBiotechnologyNot moving yet

PLRX stood above a rising 150-day average in 5 of the last 52 weekly readings, and has been out of that trend for the last 46 weeks. It is 22.2% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 46
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$327K
Officials’ trades on record
0
Institutions holding
82 (-1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 5 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1.4M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months4
Buyers · sellers0 · 4
WhoDidSharesTraded
Minnie KuoChief Operating Officersold6,917at $1.2820 Jan 2026filed 22 Jan 2026
Bernard CouliePresident and CEOsold89,375at $1.2820 Jan 2026filed 22 Jan 2026
Lily CheungChief Human Resource Officersold7,534at $1.2820 Jan 2026filed 22 Jan 2026
Keith Lamont CummingsChief Financial Officersold24,002at $1.2820 Jan 2026filed 22 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders82-1 on the quarter
New · exited10 · 12
Reported value$51.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
TANG CAPITAL MANAGEMENT LLCreduced · filed 14 Aug 20266,141,261$7.0M-1,8710.0%
ADAR1 Capital Management, LLCadded · filed 14 Aug 20265,509,724$6.3M+2,924,598+113.1%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,440,351$2.8M+97,250+4.2%
TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 20262,262,832$2.6M+9,694+0.4%
CITADEL ADVISORS LLCreduced · filed 14 Aug 20262,142,226$2.4M-1,084,373−33.6%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 20262,049,874$2.3M+197,032+10.6%
Monaco Asset Management SAMunchanged · filed 7 Aug 20261,938,747$2.2M00.0%
Lynx1 Capital Management LPnew · filed 12 Aug 20261,798,070$2.0M+1,798,070
BML Capital Management, LLCunchanged · filed 7 Aug 20261,546,137$1.8M00.0%
Prosight Management, LPreduced · filed 14 Aug 20261,370,233$1.6M-297,367−17.8%
31 Mar 2023 – 30 Jun 2026
84112140Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

David Raben Company insiderChief Medical Officer · last 1 Oct 20260 · 0
Flavia Borellini Company insiderDirector · last 9 Jul 20260 · 0
Robert Iannone Company insiderDirector · last 9 Jul 20260 · 0
Darren S. Cline Company insiderDirector · last 11 Jun 20260 · 0
Gayle A. Crowell Company insiderDirector · last 11 Jun 20260 · 0
Hoyoung Huh Company insiderDirector · last 11 Jun 20260 · 0
John T. Curnutte Company insiderDirector · last 11 Jun 20260 · 0
Steve E. Krognes Company insiderDirector · last 11 Jun 20260 · 0
Thomas A. McCourt Company insiderDirector · last 11 Jun 20260 · 0
Bernard Coulie Company insiderPresident and CEO · last 17 Apr 20260 · 31
Keith Lamont Cummings Company insiderChief Financial Officer · last 17 Apr 20260 · 9
Lily Cheung Company insiderChief Human Resource Officer · last 17 Apr 20260 · 2

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-74.9%
Share count trendFY 2025 · to 5 Mar 20260.8%
Cash and equivalentsFY 2025 · to 31 Dec 2025$45.4M
Free cash flowFY 2025 · to 31 Dec 2025−$128.7M

Analyst forecasts

No analyst forecasts yet.